Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T19:46:23.867Z.
Consensus retrieved: 2026-10-06T09:56:55.840Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T19:46:23.867Z.
Quote observation: 2026-10-06T19:45:12.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: d42caa3e816b0495fa2340ecfe28e9cd39b3fd8bb52e96b9f838481ccca068c7
Forward PE Ratio (N/A) = Dated Quote Price ($2.81) / Consensus Forward EPS ($-0.87)
FORWARD PE RATIO
N/A
C4 Therapeutics, Inc.
Market Cap
$310.69M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | $310.69M | N/A |
| Benitec Biopharma Inc. (BNTC)vs › | $310.05M | N/A |
| Agenus Inc. (AGEN)vs › | $315.04M | 28.28 |
| Avita Medical Inc. (RCEL)vs › | $320.10M | N/A |
| Sanara MedTech Inc. (SMTI)vs › | $321.76M | 184.21 |
| CapsoVision, Inc. (CV)vs › | $325.76M | N/A |
| Cabaletta Bio, Inc. (CABA)vs › | $326.60M | N/A |
| Mobia Medical, Inc. Common Stock (MOBI)vs › | $293.59M | N/A |
| ClearPoint Neuro, Inc. (CLPT)vs › | $328.54M | N/A |
| Indaptus Therapeutics, Inc. (INDP)vs › | $290.47M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $2.81, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-0.87 | $-0.92 – $-0.82 | 4 | n/m |
| 2027-12-31 | $-0.96 | $-1.04 – $-0.88 | 4 | n/m |
| 2028-12-31 | $-1.24 | $-1.75 – $-0.91 | 5 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
